BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Quinlan MP, Quatela SE, Philips MR, Settleman J. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol. 2008;28:2659-2674. [PMID: 18268007 DOI: 10.1128/mcb.01661-07] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Cameron DP, Grosser J, Ladigan S, Kuzin V, Iliopoulou E, Wiegard A, Benredjem H, Liffers ST, Lueong S, Cheung PF, Vangala D, Pohl M, Viebahn R, Teschendorf C, Wolters H, Usta S, Geng K, Kutter C, Arsenian-henriksson M, Siveke JT, Tannapfel A, Schmiegel W, Hahn SA, Baranello L. Co-inhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancerviareadthrough transcription.. [DOI: 10.1101/2023.02.10.527824] [Reference Citation Analysis]
2 Li M, Tao J, Qian R, Jiang F, Song Y, Zeng Z, Cai C. Development of alternative herbals remedy for gastric cancer based on transcriptomic analysis of immune infiltration and ferroptosis. Front Genet 2023;14:1086368. [PMID: 36936437 DOI: 10.3389/fgene.2023.1086368] [Reference Citation Analysis]
3 Asimgil H, Ertetik U, Çevik NC, Ekizce M, Doğruöz A, Gökalp M, Arık-Sever E, Istvanffy R, Friess H, Ceyhan GO, Demir IE. Targeting the undruggable oncogenic KRAS: the dawn of hope. JCI Insight 2022;7:e153688. [PMID: 35014625 DOI: 10.1172/jci.insight.153688] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
4 Cheng DK, Oni TE, Thalappillil JS, Park Y, Ting HC, Alagesan B, Prasad NV, Addison K, Rivera KD, Pappin DJ, Van Aelst L, Tuveson DA. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Proc Natl Acad Sci U S A 2021;118:e2016904118. [PMID: 34021083 DOI: 10.1073/pnas.2016904118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
5 Kattan WE, Hancock JF. RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics. Biochem J 2020;477:2893-919. [PMID: 32797215 DOI: 10.1042/BCJ20190839] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Chippalkatti R, Abankwa D. Promotion of cancer cell stemness by Ras. Biochem Soc Trans 2021;49:467-76. [PMID: 33544116 DOI: 10.1042/BST20200964] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
7 Cheng DK, Oni TE, Park Y, Thalappillil JS, Ting H, Alagesan B, Prasad N, Rivera KD, Pappin DJ, Van Aelst L, Tuveson DA. Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancer.. [DOI: 10.1101/2020.09.14.295394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Rodrigues FS, Miranda VS, Carneiro-Lobo TC, Scalabrini LC, Kruspig B, Levantini E, Murphy DJ, Bassères DS. IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells. Int J Mol Sci 2020;21:E5806. [PMID: 32823550 DOI: 10.3390/ijms21165806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Rásó E. Splice variants of RAS-translational significance. Cancer Metastasis Rev 2020;39:1039-49. [PMID: 32772213 DOI: 10.1007/s10555-020-09920-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Li JH, McMillan RH, Begum A, Gocke CB, Matsui W. IQGAP1 Maintains Pancreatic Ductal Adenocarcinoma Clonogenic Growth and Metastasis. Pancreas 2019;48:94-8. [PMID: 30540680 DOI: 10.1097/MPA.0000000000001198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mo SP, Coulson JM, Prior IA. RAS variant signalling. Biochem Soc Trans 2018;46:1325-32. [PMID: 30287508 DOI: 10.1042/BST20180173] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 8.8] [Reference Citation Analysis]
12 Kubara K, Yamazaki K, Ishihara Y, Naruto T, Lin HT, Nishimura K, Ohtaka M, Nakanishi M, Ito M, Tsukahara K, Morio T, Takagi M, Otsu M. Status of KRAS in iPSCs Impacts upon Self-Renewal and Differentiation Propensity. Stem Cell Reports 2018;11:380-94. [PMID: 29983389 DOI: 10.1016/j.stemcr.2018.06.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
13 Posada IMD, Lectez B, Sharma M, Oetken-Lindholm C, Yetukuri L, Zhou Y, Aittokallio T, Abankwa D. Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner. Oncotarget 2017;8:44550-66. [PMID: 28562352 DOI: 10.18632/oncotarget.17819] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
14 Sadacca B, Hamy AS, Laurent C, Gestraud P, Bonsang-Kitzis H, Pinheiro A, Abecassis J, Neuvial P, Reyal F. New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels. Sci Rep 2017;7:15126. [PMID: 29123141 DOI: 10.1038/s41598-017-14770-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
15 Titus HE, López-Juárez A, Silbak SH, Rizvi TA, Bogard M, Ratner N. Oligodendrocyte RasG12V expressed in its endogenous locus disrupts myelin structure through increased MAPK, nitric oxide, and notch signaling. Glia 2017;65:1990-2002. [PMID: 28856719 DOI: 10.1002/glia.23209] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
16 Posada IMD, Lectez B, Siddiqui FA, Oetken-Lindholm C, Sharma M, Abankwa D. Opposite feedback from mTORC1 to H-ras and K-ras4B downstream of SREBP1. Sci Rep 2017;7:8944. [PMID: 28827765 DOI: 10.1038/s41598-017-09387-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
17 Simanshu DK, Nissley DV, McCormick F. RAS Proteins and Their Regulators in Human Disease. Cell 2017;170:17-33. [PMID: 28666118 DOI: 10.1016/j.cell.2017.06.009] [Cited by in Crossref: 826] [Cited by in F6Publishing: 883] [Article Influence: 137.7] [Reference Citation Analysis]
18 Kuracha MR, Thomas P, Loggie BW, Govindarajan V. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies. PLoS One 2017;12:e0179510. [PMID: 28640835 DOI: 10.1371/journal.pone.0179510] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
19 Le Rolle AF, Chiu TK, Zeng Z, Shia J, Weiser MR, Paty PB, Chiu VK. Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation. Oncotarget 2016;7:2159-74. [PMID: 26744320 DOI: 10.18632/oncotarget.6818] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
20 Siljamäki E, Abankwa D. SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling. Mol Cell Biol 2016;36:2612-25. [PMID: 27503857 DOI: 10.1128/MCB.00191-16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
21 Gocke CB, McMillan R, Wang Q, Begum A, Penchev VR, Ali SA, Borrello I, Huff CA, Matsui W. IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal. Mol Cancer Ther 2016;15:2733-9. [PMID: 27573425 DOI: 10.1158/1535-7163.MCT-16-0323] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
22 Waters AM, Friedman GK, Ring EK, Beierle EA. Oncolytic virotherapy for pediatric malignancies: future prospects.Oncolytic Virother. 2016;5:73-80. [PMID: 27579298 DOI: 10.2147/OV.S96932] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
23 Posada IM, Serulla M, Zhou Y, Oetken-Lindholm C, Abankwa D, Lectez B. ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold. PLoS One 2016;11:e0159677. [PMID: 27437940 DOI: 10.1371/journal.pone.0159677] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
24 Bender RH, Haigis KM, Gutmann DH. Activated k-ras, but not h-ras or N-ras, regulates brain neural stem cell proliferation in a raf/rb-dependent manner. Stem Cells 2015;33:1998-2010. [PMID: 25788415 DOI: 10.1002/stem.1990] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
25 Najumudeen AK, Jaiswal A, Lectez B, Oetken-Lindholm C, Guzmán C, Siljamäki E, Posada IM, Lacey E, Aittokallio T, Abankwa D. Cancer stem cell drugs target K-ras signaling in a stemness context. Oncogene 2016;35:5248-62. [PMID: 26973241 DOI: 10.1038/onc.2016.59] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 9.3] [Reference Citation Analysis]
26 Vo U, Vajpai N, Flavell L, Bobby R, Breeze AL, Embrey KJ, Golovanov AP. Monitoring Ras Interactions with the Nucleotide Exchange Factor Son of Sevenless (Sos) Using Site-specific NMR Reporter Signals and Intrinsic Fluorescence. J Biol Chem 2016;291:1703-18. [PMID: 26565026 DOI: 10.1074/jbc.M115.691238] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
27 Cheung WK, Nguyen DX. Lineage factors and differentiation states in lung cancer progression. Oncogene 2015;34:5771-80. [PMID: 25823023 DOI: 10.1038/onc.2015.85] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
28 Yan ZH, Cui LH, Wang XH, Li C, He X. Comparative study of mutations in SNP loci of K-RAS, hMLH1 and hMSH2 genes in neoplastic intestinal polyps and colorectal cancer. World J Gastroenterol 2014; 20(48): 18338-18345 [PMID: 25561800 DOI: 10.3748/wjg.v20.i48.18338] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
29 Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, Fu K, Martin BL, Jeck WR, Souroullas GP, Darr DB, Zedek DC, Miley MJ, Baguley BC, Campbell SL, Sharpless NE. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov 2014;4:1418-29. [PMID: 25252692 DOI: 10.1158/2159-8290.CD-14-0729] [Cited by in Crossref: 139] [Cited by in F6Publishing: 147] [Article Influence: 15.4] [Reference Citation Analysis]
30 Bhat-Nakshatri P, Goswami CP, Badve S, Sledge GW, Nakshatri H. Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Sci Rep. 2013;3:2530. [PMID: 23982413 DOI: 10.1038/srep02530] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
31 Sumita K, Yoshino H, Sasaki M, Majd N, Kahoud ER, Takahashi H, Takeuchi K, Kuroda T, Lee S, Charest PG, Takeda K, Asara JM, Firtel RA, Anastasiou D, Sasaki AT. Degradation of activated K-Ras orthologue via K-Ras-specific lysine residues is required for cytokinesis. J Biol Chem 2014;289:3950-9. [PMID: 24338482 DOI: 10.1074/jbc.M113.531178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
32 Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci USA. 2013;110:20723-20728. [PMID: 24297898 DOI: 10.1073/pnas.1314307110] [Cited by in Crossref: 195] [Cited by in F6Publishing: 203] [Article Influence: 19.5] [Reference Citation Analysis]
33 Fukui T, Shaykhiev R, Agosto-Perez F, Mezey JG, Downey RJ, Travis WD, Crystal RG. Lung adenocarcinoma subtypes based on expression of human airway basal cell genes. Eur Respir J. 2013;42:1332-1344. [PMID: 23645403 DOI: 10.1183/09031936.00144012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
34 Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA Jr, Pao W. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res 2013;19:2584-91. [PMID: 23515407 DOI: 10.1158/1078-0432.CCR-12-3173] [Cited by in Crossref: 97] [Cited by in F6Publishing: 110] [Article Influence: 9.7] [Reference Citation Analysis]
35 Auffinger B, Ahmed AU, Lesniak MS. Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice. Front Oncol 2013;3:32. [PMID: 23443138 DOI: 10.3389/fonc.2013.00032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
36 Lampson BL, Pershing NL, Prinz JA, Lacsina JR, Marzluff WF, Nicchitta CV, MacAlpine DM, Counter CM. Rare codons regulate KRas oncogenesis. Curr Biol 2013;23:70-5. [PMID: 23246410 DOI: 10.1016/j.cub.2012.11.031] [Cited by in Crossref: 113] [Cited by in F6Publishing: 116] [Article Influence: 10.3] [Reference Citation Analysis]
37 Patmore DM, Welch S, Fulkerson PC, Wu J, Choi K, Eaves D, Kordich JJ, Collins MH, Cripe TP, Ratner N. In vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1. Cancer Res 2012;72:5317-27. [PMID: 22918885 DOI: 10.1158/0008-5472.CAN-12-1972] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
38 Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72:2457-2467. [PMID: 22589270 DOI: 10.1158/0008-5472.can-11-2612] [Cited by in Crossref: 1254] [Cited by in F6Publishing: 1295] [Article Influence: 114.0] [Reference Citation Analysis]
39 Wang Z, Feng Y, Bardeesy N, Wong KK, Liu XY, Ji H. Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele. PLoS One 2012;7:e37308. [PMID: 22606359 DOI: 10.1371/journal.pone.0037308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
40 Friedman GK, Cassady KA, Beierle EA, Markert JM, Gillespie GY. Targeting pediatric cancer stem cells with oncolytic virotherapy. Pediatr Res 2012;71:500-10. [PMID: 22430386 DOI: 10.1038/pr.2011.58] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
41 Ho C, Wang C, Mattu S, Destefanis G, Ladu S, Delogu S, Armbruster J, Fan L, Lee SA, Jiang L, Dombrowski F, Evert M, Chen X, Calvisi DF. AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. Hepatology 2012;55:833-45. [PMID: 21993994 DOI: 10.1002/hep.24736] [Cited by in Crossref: 141] [Cited by in F6Publishing: 151] [Article Influence: 12.8] [Reference Citation Analysis]
42 Westerman BA, Braat AK, Taub N, Potman M, Vissers JH, Blom M, Verhoeven E, Stoop H, Gillis A, Velds A, Nijkamp W, Beijersbergen R, Huber LA, Looijenga LH, van Lohuizen M. A genome-wide RNAi screen in mouse embryonic stem cells identifies Mp1 as a key mediator of differentiation. J Exp Med 2011;208:2675-89. [PMID: 22143885 DOI: 10.1084/jem.20102037] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
43 O'Hagan RC, Heyer J. KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations. Genes Cancer 2011;2:335-43. [PMID: 21779503 DOI: 10.1177/1947601911408080] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
44 Castellano E, Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer 2011;2:216-31. [PMID: 21779495 DOI: 10.1177/1947601911408081] [Cited by in Crossref: 187] [Cited by in F6Publishing: 197] [Article Influence: 15.6] [Reference Citation Analysis]
45 Arozarena I, Calvo F, Crespo P. Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events. Genes Cancer 2011;2:182-94. [PMID: 21779492 DOI: 10.1177/1947601911409213] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
46 Zhong W, Chen M, Xian L, Li M. [Study on point mutations of K-ras gene in non-small cell lung cancer in Guangxi]. Zhongguo Fei Ai Za Zhi 2011;14:507-11. [PMID: 21645454 DOI: 10.3779/j.issn.1009-3419.2011.06.06] [Reference Citation Analysis]
47 Abedin Z, Sen S, Morocco E, Field J. p53 and Ras Mutations in Cancer and Experimental Carcinogenesis. Chemical Carcinogenesis 2011. [DOI: 10.1007/978-1-61737-995-6_18] [Reference Citation Analysis]
48 Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood 2011;117:2022-32. [PMID: 21163920 DOI: 10.1182/blood-2010-04-280750] [Cited by in Crossref: 109] [Cited by in F6Publishing: 112] [Article Influence: 8.4] [Reference Citation Analysis]
49 Vartak N, Bastiaens P. Spatial cycles in G-protein crowd control. EMBO J 2010;29:2689-99. [PMID: 20717139 DOI: 10.1038/emboj.2010.184] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
50 Hölzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R, Bernards R. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010;142:218-29. [PMID: 20655465 DOI: 10.1016/j.cell.2010.06.004] [Cited by in Crossref: 162] [Cited by in F6Publishing: 163] [Article Influence: 12.5] [Reference Citation Analysis]
51 Wen J, Park JY, Park KH, Chung HW, Bang S, Park SW, Song SY. Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Pancreas 2010;39:622-6. [PMID: 20173672 DOI: 10.1097/MPA.0b013e3181c75f5e] [Cited by in Crossref: 98] [Cited by in F6Publishing: 107] [Article Influence: 7.5] [Reference Citation Analysis]
52 Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69-80. [PMID: 20371346 DOI: 10.1016/j.cell.2010.02.027] [Cited by in Crossref: 1702] [Cited by in F6Publishing: 1785] [Article Influence: 130.9] [Reference Citation Analysis]
53 Lau KS, Haigis KM. Non-redundancy within the RAS oncogene family: insights into mutational disparities in cancer. Mol Cells 2009;28:315-20. [PMID: 19812895 DOI: 10.1007/s10059-009-0143-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
54 Henis YI, Hancock JF, Prior IA. Ras acylation, compartmentalization and signaling nanoclusters (Review). Mol Membr Biol 2009;26:80-92. [PMID: 19115142 DOI: 10.1080/09687680802649582] [Cited by in Crossref: 98] [Cited by in F6Publishing: 85] [Article Influence: 6.5] [Reference Citation Analysis]
55 Belda-Iniesta C, Ibáñez de Cáceres I, Barriuso J, de Castro Carpeño J, González Barón M, Feliú J. Molecular biology of pancreatic cancer. Clin Transl Oncol 2008;10:530-7. [PMID: 18796369 DOI: 10.1007/s12094-008-0247-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
56 Saliani M, Jalal R, Ahmadian MR. From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers. Cancer Biol Med 2019;16:435-61. [PMID: 31565476 DOI: 10.20892/j.issn.2095-3941.2018.0530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Reference Citation Analysis]